Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
AssigneeZymoGenetics, Inc.
InventorPaul O. Sheppard
Life of this patent
Estimating the term…
Abstract
Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
Claims14
A method of delaying a relapse of relapsing-remitting multiple sclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a polypeptide encoded by a polynucleotide of SEQ ID NO:174, wherein the encoded polypeptide comprises amino acid residues 1-176 of SEQ ID NO:175.
The method of claim 2, wherein the polypeptide is conjugated to a polyalkyl oxide moiety.
A method of delaying a relapse of relapsing-remitting multiple sclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a formulation comprising a polypeptide encoded by a polynucleotide of SEQ ID NO:174 and a pharmaceutically acceptable vehicle, wherein the encoded polypeptide comprises amino acid residues 1-176 of SEQ ID NO:175.
Dependencies are inferred from the claim text.